These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 8425137)

  • 1. Assessment of costs and benefits of drug therapy for treatment-resistant schizophrenia in the United Kingdom.
    Davies LM; Drummond MF
    Br J Psychiatry; 1993 Jan; 162():38-42. PubMed ID: 8425137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clozapine: an appraisal of its pharmacoeconomic benefits in the treatment of schizophrenia.
    Fitton A; Benfield P
    Pharmacoeconomics; 1993 Aug; 4(2):131-56. PubMed ID: 10146973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia.
    Meltzer HY; Cola P; Way L; Thompson PA; Bastani B; Davies MA; Snitz B
    Am J Psychiatry; 1993 Nov; 150(11):1630-8. PubMed ID: 8105705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modelling the impact of clozapine on suicide in patients with treatment-resistant schizophrenia in the UK.
    Duggan A; Warner J; Knapp M; Kerwin R
    Br J Psychiatry; 2003 Jun; 182():505-8. PubMed ID: 12777341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple outcome assessment in a study of the cost-effectiveness of clozapine in the treatment of refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.
    Rosenheck R; Cramer J; Xu W; Grabowski J; Douyon R; Thomas J; Henderson W; Charney D
    Health Serv Res; 1998 Dec; 33(5 Pt 1):1237-61. PubMed ID: 9865219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Business Case for Expanded Clozapine Utilization.
    Gören JL; Rose AJ; Smith EG; Ney JP
    Psychiatr Serv; 2016 Nov; 67(11):1197-1205. PubMed ID: 27301766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Medico-economic study of Léponex (clozapine) in the Bordeaux Charles Perrens Hospital Center].
    Bret P; Jolivel C; Bret MC; Veylit S; Martin C; Garcia P
    Encephale; 1998; 24(4):365-77. PubMed ID: 9809242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Medico-economic evaluation of treatment with clozapine versus treatment with previous neuroleptics].
    Geronimi-Ferret D; Lesay M; Barges-Bertocchio MH; Cornet-Bonnefont M; Robert H
    Encephale; 1997 Sep; 23 Spec No 4():24-31. PubMed ID: 9417402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pharmacoeconomics of clozapine: a review.
    Meltzer HY; Cola PA
    J Clin Psychiatry; 1994 Sep; 55 Suppl B():161-5. PubMed ID: 7961564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of clozapine monitoring after the first 6 months.
    Zhang M; Owen RR; Pope SK; Smith GR
    Arch Gen Psychiatry; 1996 Oct; 53(10):954-8. PubMed ID: 8857873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacoeconomic evaluation of treatments for refractory schizophrenia: clozapine-related studies.
    Revicki DA
    J Clin Psychiatry; 1999; 60 Suppl 1():7-11; discussion 28-30. PubMed ID: 10037164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of clozapine treatment in therapy-refractory schizophrenia.
    Jonsson D; Wålinder J
    Acta Psychiatr Scand; 1995 Sep; 92(3):199-201. PubMed ID: 7484198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-benefit analysis of risperidone and clozapine in the treatment of schizophrenia in Israel.
    Ginsberg G; Shani S; Lev B
    Pharmacoeconomics; 1998 Feb; 13(2):231-41. PubMed ID: 10178649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Should clozapine continue to be restricted to third-line status for schizophrenia?: a decision-analytic model.
    Wang PS; Ganz DA; Benner JS; Glynn RJ; Avorn J
    J Ment Health Policy Econ; 2004 Jun; 7(2):77-85. PubMed ID: 15208468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generic replacement of clozapine: a simple decision model from a Canadian perspective.
    Layton S; Barbeau M
    Curr Med Res Opin; 2004 Apr; 20(4):453-9. PubMed ID: 15119982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacoeconomic evaluation of clozapine in treatment-resistant schizophrenia: a cost-utility analysis.
    Oh PI; Iskedjian M; Addis A; Lanctôt K; Einarson TR
    Can J Clin Pharmacol; 2001; 8(4):199-206. PubMed ID: 11743592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New vs. old antipsychotics: the Texas experience.
    Reid WH
    J Clin Psychiatry; 1999; 60 Suppl 1():23-5; discussion 28-30. PubMed ID: 10037167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of clozapine. A UK clinic-based study.
    Aitchison KJ; Kerwin RW
    Br J Psychiatry; 1997 Aug; 171():125-30. PubMed ID: 9337946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenetic testing in the clinical management of schizophrenia: a decision-analytic model.
    Perlis RH; Ganz DA; Avorn J; Schneeweiss S; Glynn RJ; Smoller JW; Wang PS
    J Clin Psychopharmacol; 2005 Oct; 25(5):427-34. PubMed ID: 16160617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of sole nurse and team-delivered community clozapine services for people with treatment-resistant schizophrenia.
    Gage H; Family H; Murphy F; Williams P; Sutton J; Taylor D
    J Adv Nurs; 2015 Mar; 71(3):547-58. PubMed ID: 25376164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.